



Goldline Pharmaceutical Limited

CIN.: U51397MH2004PLC147806

Date: May 11, 2026

To,
The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001

Dear Sir,

Sub: Public Issue of equity shares of face value of Rs. 10/- each of Goldline Pharmaceutical Limited ("Company" and "Issue", respectively)

The Board of Directors of the Company at its meeting held on May 11, 2026, in consultation with the Book Running Lead Manager to the Issue, has finalized allocation of 7,32,000 Equity Shares, to Anchor Investors at Anchor Investor allocation price of Rs. 43 per Equity Share (including share premium of Rs. 33 per Equity Share) in the following manner:

Sr. No.	Name of the Anchor Investor	No. of Equity Shares allocated	Total amount (₹)	% of Anchor Investor Portion	Bid price (Rs. per Equity Share)
1.	Upsurge Opportunities Fund I	3,66,000	1,57,38,000	50.00%	43
2.	Vikasa India EIF I Fund – Share Class P	3,66,000	1,57,38,000	50.00%	43
Total		7,32,000	3,14,76,000	100.00%	

No Mutual Funds have applied through any schemes, scheme-wise details provided in table below:

Sr. No.	Name of Scheme	No. of Equity Shares allocated	% of Anchor Investor Portion	Bid price (Rs. per Equity Share)
1.	NIL	NIL	NIL	NIL

As per the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirement) Regulations, 2009, as amended, in case the Issue Price discovered through book building process is higher than the Anchor Investor allocation price, Anchor investors will be required to pay the difference by the pay-in as specified in the revised CAN.

Please note that capitalized terms used and not defined herein shall have the respective meaning ascribed to them in the Red Herring Prospectus.

We request you to make the above information public by disclosing the same on your website.

Yours faithfully,

For Goldline Pharmaceutical Limited

Amol Laxmilkant Mujumdar
Managing Director
DIN:01910549
Date: May 11, 2026
Place: Nagpur, Maharashtra

